



International Federation
of Health Plans

2015 Comparative Price Report
Variation in Medical and Hospital Prices by Country

International Federation of Health Plans



The International Federation of Health Plans is the leading global network of the health insurance industry, with 80 members in 25 countries. Founded in Australia in 1972 and now based in London, it seeks to unite the industry through events and educational programmes, and assist in the maintenance of high professional standards.

2015 Survey Overview

This year's survey has been conducted in much the same way as the previous study, which includes pricing for several specialty prescription drugs, other prescription drugs and a selection of typical medical procedures. Prices for each country were submitted by participating federation member plans, and are drawn from public or commercial sectors as follows:


- Prices for the United States were derived from over 370 million medical claims and over 170 million pharmacy claims that reflect prices negotiated and paid to health care providers.
- Prices for Australia, New Zealand, Spain, South Africa, Switzerland and the UK are from the private sector, with data provided by one private health plan in each country.

Comparisons across different countries are complicated by differences in sectors, fee schedules, and systems. In addition, a single plan's prices may not be representative of prices paid by other plans in that market. *

* Figures, when compared to previous studies, are affected by strength of US dollar.

Drugs: Xarelto

Xarelto is prescribed to prevent or treat blood clots.




Xarelto, 30 capsules, 20mg, 30 day supply

Drugs: Humira



Humira is prescribed to treat rheumatoid arthritis.




Humira, 1 prefilled syringe carton, 2 syringes, 28 day supply

Drugs: Harvoni



International Federation of Health Plans

Harvoni is prescribed to treat hepatitis C.



Harvoni, 28 tablets, 4-week supply

Drugs: Truvada




Truvada is prescribed to treat HIV/AIDS.



Truvada, 30 tablets, 30 day supply

Drugs: Tecfidera

Tecfidera is prescribed to treat relapsing multiple sclerosis.




Tecfidera, 60 capsules, 240 mg, 30 day supply

Drugs: Avastin



Avastin is prescribed to treat certain types of cancer.




Avastin, 400 mg vial

Drugs: OxyContin




OxyContin is prescribed to treat severe ongoing pain.




Oxycontin, 60 tablets, 20 mg, 30+ day supply


Diagnostics: Angiogram




Diagnostics: CT Scan Abdomen




Diagnostics: MRI




Diagnostics: Colonoscopy




Diagnostics: Cardiac Catheterization




Hospital Cost per Day




Total Hospital and Physician: Appendectomy



Total Hospital and Physician: Normal Delivery




Total Hospital and Physician: C-Section



Total Hospital and Physician: Cataract Surgery

\$8,377




\$USD

■ Average Price


● USA 25th Percentile

● USA 95th Percentile

Total Hospital and Physician: Knee Replacement




Total Hospital and Physician: Hip Replacement



Total Hospital and Physician: Bypass Surgery

\$161,148




\$USD

■ Average Price

● USA 25th Percentile

● USA 95th Percentile

Total Hospital and Physician: Angioplasty



Notes

United States

The price estimates were provided by the Health Care Cost Institute (HCCI) in collaboration with iFHP. The prices reported are the average allowed costs, which include both member cost sharing and health plan payment.

The source of the data used for this study was limited to employer-sponsored insurance (ESI) claims held by HCCI. The values reported are estimates of 2014 prices based on 2014 claims. No trend assumptions were applied to the data. The dataset contains ESI incurred from 1/1/2014 to 12/31/2014, and paid through 6/30/2015. These data do not include claims without membership records or claims with membership without a valid funding type. No demographic or geographic exclusion criteria were applied for this study. Additionally, actuarial completion was not applied to the claims in the dataset.

The preliminary average price estimates were compared to multiple data sources including the 2013 iFHP report, guroo.com (HCCI's price transparency initiative), and various other publicly available data to validate the findings.

As a broad range of prices were available, the national 25th percentile (low), average, and 95th percentile were calculated to provide context on the extent of commercial price variation.